Also found in: Wikipedia.


(con-i-vap-tan) ,


(trade name)


Therapeutic: electrolyte modifiers
Pharmacologic: vasopressin antagonists
Pregnancy Category: C


To increase serum sodium in hospitalized patients with euvolemic or hypervolemic hyponatremia.


Antagonizes vasopressin at V2 receptor sites in renal collecting ducts, resulting in excretion of free water.

Therapeutic effects

Increased serum sodium concentrations.
Improved fluid status.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Protein Binding: 99% protein bound.
Metabolism and Excretion: Metabolized solely by the CYP3A4 enzyme system. 83% excreted in feces as metabolites, 12% in urine (as metabolites).
Half-life: 5 hr.

Time/action profile

IVunknown12 hrend of infusion


Contraindicated in: Hypersensitivity;Hypovolemic hyponatremia;Concurrent use of ketonconazole, itraconazole, clarithromycin, ritonavir, or indinavir.
Use Cautiously in: Moderate hepatic impairment (↓ dose recommended)Severe renal impairment (not recommended if CCr <30 mL/min); Obstetric / Lactation: Safety not established; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • confusion
  • insomnia


  • hypertension
  • hypotension


  • diarrhea


  • polyuria

Fluid and Electrolyte

  • dehydration
  • hypokalemia
  • hypomagnesemia
  • hyponatremia


  • infusion reactions (most frequent)


  • fever
  • thirst


Drug-Drug interaction

Blood levels and effects are ↑ by ketoconazole, itraconazole, clarithromycin, ritonavir, or indinavir ; concurrent use is contraindicated.↑ blood levels and may ↑ effects of midazolam, simvastatin, lovastatin, amlodipine, and other drugs metabolized by CYP3A4 ; careful monitoring recommended.May ↑ digoxin levels.


Intravenous (Adults) 20 mg loading dose initially, followed by 20 mg/day as a continuous infusion for 2–4 days. May titrate conivaptan up to 40 mg/day as a continuous infusion if serum sodium is not rising at desired rate. Total duration of therapy should not exceed 4 days.

Hepatic Impairment

(Adults) Moderate hepatic impairment—10 mg loading dose initially, followed by 10 mg/day as a continuous infusion for 2–4 days; may titrate up to 20 mg/day as a continuous infusion if serum sodium is not rising at desired rate.


Premixed infusion: 20 mg/100 mL D5W

Nursing implications

Nursing assessment

  • Monitor injection site during administration. Frequently causes erythema, pain, swelling and phlebitis. May require discontinuation of therapy.
  • Monitor vital signs frequently during therapy. Discontinue therapy if patient becomes hypovolemic and hypotensive. Therapy may be resumed at a reduced dose once patient is euvolemic and no longer hypotensive, if patient remains hyponatremic.
  • Assess neurologic status during administration. Overly rapid rise in serum sodium may cause neurologic sequelae.
  • Lab Test Considerations: Monitor serum sodium concentration frequently during therapy. If serum sodium rises at an undesirably rapid rate (>12 mEq/L/24 hr), discontinue administration of conivaptan. If serum sodium continues to rise, do not resume therapy. If hyponatremia persists or recurs (after discontinuation for rapid rise of serum sodium) and patient has no evidence of neurologic sequelae from rapid increase, conivaptan may be resumed at a reduced dose.
    • May cause hyperglycemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Intravenous Administration
  • Administer IV through large veins and rotate infusion site every 24 hr to minimize risk if vascular irritation.
  • Loading Dose
  • Intermittent Infusion: Diluent: Premixed containers require no further dilution.Concentration: 0.2 mg/mL.
  • Rate: Administer over 30 min.
  • Continuous Infusion
  • Continuous Infusion: Diluent: Premixed containers require no further dilution.Concentration: 0.2 mg/mL.
  • Rate: Administer continuous infusion at a rate of 20 mg/24 hr. If patient requires 40 mg/24 hr continuous infusion, infuse 20 mg over 12 hr, followed by 20 mg over 12 hr.
  • Additive Incompatibility: Do not admix with LR, furosemide, or combine with any other product in the same IV line or bag.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Instruct patient to notify health care professional if pain or redness occurs at infusion site.

Evaluation/Desired Outcomes

  • Restoration of normal fluid and electrolyte balance.


a vasopressin receptor antagonist.
indications This drug is used to treat euvolemia hyponatremia in those hospitalized.
contraindications Hypovolemia and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects of this drug include headache, confusion, insomnia, hypotension, hypertension, orthostatic hypotension, phlebitis, nausea, vomiting, constipation, dry mouth, hematuria, polyuria, urinary tract infection, pollaklura, anemia, erythema, injection site reaction, dehydration, hyperglycemia, hypoglycemia, hypokalemia, hypomagnesia, hyponatremia, oral candidiasis, pain, peripheral edema, and pneumonia. Atrial fibrillation is a life-threatening side effect.
References in periodicals archive ?
Clinically significant elevations in liver enzymes were reported in 1 placebo patient, 9 of 29 conivaptan 40 mg/day patients, and 13 of 26 conivaptan 80 mg/day patients.
Both doses of conivaptan significantly increased effective water clearance, compared with placebo.
Both conivaptan doses significantly increased serum sodium levels over the 4 days, compared with placebo, with a mean change in AUC of 491 mEq/L per hour in the conivaptan 40 mg/day group, 714 mEq/L per hour in the 80-mg/day group, and 13 mEq/L per hr in the placebo group.
Treatment with conivaptan was well tolerated, with a low rate of drug-related adverse effects and few discontinuations due to adverse effects.
Patients were randomized to receive 20 mg oral conivaptan b.
During the 5 days of treatment, serum sodium levels increased in the conivaptan group in a dose-related manner and to levels that were significantly above those reached in the control group, reported Jala K.
Conivaptan, which was approved in 2005 for euvolemic hyponatremia, received approval in early 2007 for dilutional (hypervolemic) hyponatremia.
The conivaptan study was supported by Astellas Pharma US Inc.
Other investigators assessed conivaptan (Vaprisol, Astellas) and supported its use for euvolemic hyponatremia because the drug increased urine output of mostly free water with little electrolyte loss (J.
Effects of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetized dogs.
While familiarity with new agents in development including Sanofi's satavaptan, Cardiokine's lixivaptan, and Astellas's oral conivaptan is low, nephrologists report a preference for non-peptide selective vasopressin V2 receptor antagonists over V1A/V2 receptor antagonists.
Two vasopressin antagonists, or "vaptans," have been tested in clinical trials: conivaptan and tolvaptan.